Prescient Therapeutics ramps up Phase 2 trial as research reiterates valuation upside
Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset...
Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset...
Cancer remains one of the most formidable challenges in modern medicine — but it is...
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics Ltd (ASX: PTX) earlier this week received European authorisation to begin clinical trials...
As the Wise Man sayeth, one should giveth a task to a busy person if...
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential...
In a sector where the right drug emerging at the right time can yield billions, Prescient...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.